Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ponatinib in CML or Ph-positive ALL after TKI failure or with T315I mutation
CTR20192681Phase 2Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Jul 2020; status: active.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20192681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192681.